^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

AMG 305

i
Other names: AMG 305, AMG305, AMG-305
Associations
Company:
Amgen
Drug class:
CD3 agonist, Mesothelin inhibitor, CDH3 inhibitor
Related drugs:
Associations
4ms
Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=260, Recruiting, Amgen | Trial completion date: Jan 2027 --> Aug 2027 | Trial primary completion date: May 2026 --> Dec 2026
Trial completion date • Trial primary completion date • Metastases
|
MSLN (Mesothelin) • CDH3 (Cadherin 3)
|
AMG 305
8ms
Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=260, Recruiting, Amgen | Trial completion date: Oct 2026 --> Jan 2027 | Trial primary completion date: Feb 2026 --> May 2026
Trial completion date • Trial primary completion date • Metastases
|
MSLN (Mesothelin) • CDH3 (Cadherin 3)
|
AMG 305
9ms
Trial primary completion date • Metastases
|
MSLN (Mesothelin) • CDH3 (Cadherin 3)
|
AMG 305
over1year
Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors. (clinicaltrials.gov)
P1, N=260, Recruiting, Amgen | Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2026 --> Apr 2025
Enrollment open • Trial primary completion date • Metastases
|
MSLN (Mesothelin) • CDH3 (Cadherin 3)
|
AMG 305
over1year
New P1 trial • Metastases
|
MSLN (Mesothelin) • CDH3 (Cadherin 3)
|
AMG 305